Imatinib . mesylate

CGP-54148B; STI-571; Gleevec; Glivec

Imatinib mesylate is a multitarget tyrosine kinase inhibitor with antineoplastic activity. It is a potent and selective inhibitor of the kinases Bcr-Abl (IC50 = 38 nM), PDGFR and c-Kit, which are encoded by the bcr-abl oncogene as well as receptor tyrosine kinases encoded by c-Kit and platelet-derived growth factor receptor (PDGFR) oncogenes, which is useful in vitro and in vivo. Imatinib inhibits ligand-stimulated autophosphorylation of PDGFR and c-Kit and the proliferation of Bcr-Abl-dependent R10 cells and HMC-1 cells expressing constitutively active c-Kit in a concentration-dependent manner. Formulations containing imatinib have been used in the treatment of various cancers. Specifically, it is used for chronic myelogenous leukemia (CML) and acute lymphocytic leukemia (ALL) that are Philadelphia chromosome-positive (Ph+), certain types of gastrointestinal stromal tumors (GIST), hypereosinophilic syndrome (HES), chronic eosinophilic leukemia (CEL), systemic mastocytosis and myelodysplastic syndrome. Abelson (Abl) kinase inhibitors have been shown to inhibit replication of Ebola virus, coxsackievirus and vaccinia virus, but at different points of the virus life cycle. Imatinib inhibits replication of SARS-CoV and MERS-CoV in vitro by a novel mechanism of blocking coronavirus virion fusion with the endosomal membrane. Abl is also a potential drug target of SARS-CoV-2 and can possible inhibit the spread of COVID-19.

220127-57-1

C29H31N7O . CH4SO3

Determined by 1H-NMR.

YLMAHDNUQAMNNX-UHFFFAOYSA-N

Lyophilized

493.6 . 96.1

greater than or equal to 98% (HPLC)

CV5520550

CS(O)(=O)=O.CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC=C(C)C(NC3=NC=CC(=N3)C3=CN=CC=C3)=C2)CC1

Soluble in ethanol (20mg/ml), DMSO (15mg/ml) or dimtheylformamide (15mg/ml).

Soluble in ethanol (20mg/ml), DMSO (15mg/ml) or dimtheylformamide (15mg/ml).